Physician profile
Mark Defazio
NPI 1073586343
$27,415.99
in general payments reported to CMS, 2019-2025
9 companies · $1,371 in 2025
The $1,371 reported for 2025 was more than what 92% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,777 · 2021: $50.00 · 2022: $2,461 · 2023: $16K · 2024: $5,800 · 2025: $1,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Consulting Fee: $2,965 · Food and Beverage: $491 · Travel and Lodging: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,572.50 |
| Consulting Fee | $2,965.00 |
| Food and Beverage | $490.73 |
| Travel and Lodging | $100.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $22,948.50 | 2023-2025 | Veozah |
| Scynexis, INC. | $2,444.37 | 2022 | |
| Duchesnay USA Incorporated | $1,657.85 | 2019 | |
| Lupin INC. | $118.73 | 2019 | |
| Myriad Women'S Health, INC. | $96.77 | 2023 | Myrisk |
| Medtronic, INC. | $70.29 | 2025 | Linq II |
| Celularity INC. | $50.00 | 2021 | |
| Myovant Sciences INC. | $16.35 | 2022 | |
| Organon LLC | $13.13 | 2025 | Jada System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Defazio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.